Indicative publications are listed below. Please see LML members' individual pages for full publication lists.
M Aboy, C Crespo, K Liddell, N Davey, J Liddicoat, T Minssen, 'One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?', (2020) 38 Nature Biotechnology 279-283.
M Aboy, K Liddell, C Crespo, I G Cohen, J Liddicoat, S Gerke, 'How deos emerging patent case law in the US and Europe affect precision medicine?', (2019) 37 Nature Biotechnology 1118-1125.
M Aboy, C Crespo, K Liddell, T Minssen, J Liddicoat, 'Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine', (2019) 37 Nature Biotechnology 513-518.
M Aboy, C Crespo, K Liddell, J Liddicoat, M Jordan, 'Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?', (2018) 36 Nature Biotechnology 1146-1149.
M Aboy, J Liddicoat, K Liddell, M Jordan, C Crespo, 'After Myriad, what makes a gene patent claim 'markedly different' from nature?', (2017) 35 Nature Biotechnology 820-225.
M Aboy, K Liddell, J Liddicoat, C Crespo, 'Myriad's impact on gene patents', (2016) 34 Nature Biotechnology 1119-1123.
For more information about the LML's Consulting and Contract Services regarding patent landscaping, see here.
